Medical & Commercial

Featured

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

In this session, industry experts Dr. Radek Wasiak and Isabella Even-Chen break down the critical "Fit-for-Purpose Gap"—the misstep of assuming a single, generalized dataset can satisfy every study design, regulatory requirement, or health economics endpoint.

Highlight

Medical & Commercial

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

World Orphan Drug Congress Europe: October 26-28 at the RAI Convention Centre in Amsterdam

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

June 2026 Medical/Commercial Pulse Check

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

HealthEconomics.com 2026 Pulse Check – March

What the New U.S.-UK Pharmaceuticals Deal Really Means for Pricing, Access, and Global Market Dynamics

Faster Insights or Faster Fail? How to Avoid the Misuse of Real-World Data when Using AI

Using Real-World Data to Understand the Impact of IRA Policy on Patient Outcomes and Health Equity

When the Evidence Fails the Drug: Is the Role of Study Design Being Overlooked During Discovery?

Navigating Shifts in Pharmaceutical Policy: Impacts and Future Outlook

Bridging the Gap: Image Software Quantification vs. Pathologist Scoring in Histopathology

5 Key Questions to Ask Before You Launch a Value Evidence Plan

Making the HEOR Case for Targeted Therapies - From Biomarkers to Benefits

Beyond the Averages: Addressing Health Equity in an Unequal World

The New Age of HEOR - Wearables, AI, and Predictive Analytics

Women's Health Series 2024

The Policy Puzzle: How Legislation is Shaping the Future of Rare Disease Treatment

Building Data-Driven Market Access Strategies for Commercial Success

Market Access "Back to School": How to Plan and Prioritize Your 2025 Projects

ModEx: Revolutionizing Cancer Drug Pricing and Access Through Open-Source Health Economic Models

Making Real-World Data Research-Ready

From Development to Delivery: Prioritizing Market Access in Biotech and Pharma

Is Your Real-World Data Research-Ready?

Accelerating Development of Rare Genetic Disease Therapeutics

The Only Constant is Change

Advancing Health Equity by Leveraging Social Determinants of Health Data

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

Closing Gaps in Care: Health Equity and the Inflation Reduction Act - A Cutting Edge Conversation

Network meta-analysis and its role in evidence-based decision-making

Sustainable Science: Transforming Pharma-Supplier Partnerships

Addressing Orphan and Rare Diseases - A Cutting Edge Conversation

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

RWE reality check: Routine patient health records and regulatory requirements

"S" Stands for Systematic: Demystifying the Systematic Literature Review

Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned

Market Access - Transforming BioTech Commercial Decisions?

The Scientific and Operational Elegance of Study Replication with Real-World EHR Data: A Vitiligo and Alopecia Example

Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping

Insights from the 2024 Salary Survey Report by HealthEconomics.com

Beyond Accelerated Approvals: External Control Arms

Delphi Panels: What Are They Good For?

Unraveling European Animal Welfare Legislation for Biotech & Pharma

Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches

Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management

Understanding Animal Welfare Best Practices in Asia Pacific for Biotech & Pharma

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Navigating Animal Welfare Legislation in North America: Insights for Biotech & Pharma

Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters

EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025

Cell & Gene Therapies - Beginning with the End in Mind

Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Pharma can target ultra-rare conditions ‚Äî the next step is financing them

Transforming Healthcare Using Big Data and Remote Monitoring

Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation

Minimizing the Impact of Cross-Cultural Differences in COA Translations

Synthesise RWE and AI. Transform patient-driven healthcare

Endpoints at #DIA23

Tracking and Measuring Market Access Performance

Certified Corporate Wellness Specialist(CCWS): Is It For Me?

L7|LIVE SF - Tuesday, June 13th, 2023

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Connected communities: Advancing population health through data and emerging technology

Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials

The reimagined hospital: How health systems are keeping up with new tech

Clinical Trial Innovation: How Healthcare Technology is Evolving

How to assess the quality of AI output when structuring unstructured medical data

Driving value from healthcare data: How integrated cloud-based data is foundational to drive enterprise change

Advancing identity data management for digital engagement: How leading organizations are doing it

How Digital Health Can Empower Cancer Patients

Keeping up with demands for healthcare outside of the hospital: Critical ways tech supports the distributed care model

Closing the gaps of getting data to make decisions

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Medicare Part D: Price Negotiation Panel Discussion

Notice of Pre-Application Webinar for RFA-AG-24-009, "Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)"